Certain GLP-1 formulations have demonstrated cardiovascular benefits in clinical trials, leading to specific FDA approvals: Victoza, Ozempic, and Trulicity are approved for reducing major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease, while Wegovy is approved for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight
Similar to the periplasm, the GSH:GSSG ratio in the ER is lower (3:1 to 1:1) compared to the cytosol (100:1), resulting in a more oxidizing environment (Hwang et al., 1992)
Pricing will vary depending on your insurance situation
GLP-1 RAs appear to have neutral to beneficial effects on bone health in patients with type 2 diabetes, with evidence suggesting they do not increase fracture risk and may improve bone mineral density and bone turnover markers
Possible side effects may include mild injection-site irritation, temporary headaches, or brief flushing
Why are GLP-1 inhibitors so popular
